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A tetrazolium-based colorimetric selective assay (MTT-based CSA) was developed to assess the selectivity of antimalarial drugs.
This in vitro assay, unlike all others, measures the ability of drugs to indirectly protect red blood cells (RBCs) from Plasmodium-
falciparum-induced destruction. Optimum incubation time and number of cells needed were 5 days and 23 × 106 RBCs per well,
respectively. A parasitemia range of 0.375% to 3% was found to be suitable for this assay. The MTT-based CSA determined anti-P.
falciparum strain DD2 activity of chloroquine at a higher 50% eﬀective concentration (EC50) value (21.0µg/mL) than the isotopic
microtest (10.0µg/mL). Artesunate and oxytetracycline achieved 90% eﬀect against DD2 with minimal or no toxicity to RBCs.
Against chloroquine sensitive strain 3D7, chloroquine and Alchornea cordifolia had EC50 values of 0.025µg/mL and 4.9µg/mL
respectively, and selective index (SI) values of >2,000 and >69.4µg/mL, respectively.
1.Introduction
The threat of malaria has continued to plague millions of
people living in most tropical countries despite numerous
strategies to bring this disease under control. Chloroquine
used to be the ﬁrst drug of choice for the treatment of P.
falciparum infections in Ghana and many African countries,
but the emergence of drug-resistant strains has necessitated
intensive search for new drugs [1–3]. Presently, Artesunate-
Amodiaquine and Artesunate-Lumefantrine combinations
are ﬁrst-choice drugs in Ghana. The standard World Health
Organization (WHO) method for testing new antimalar-
ial drugs involves tedious microscopic parasite counting
method (MPCM). Other in vitro methods are haem poly-
merization inhibition assay (HPIA) [4], lactate dehydroge-
nase assay (LDHA) [5, 6] and the isotopic microtest (IMT)
[7]. All these in vitro tests measure some activity of the
parasite and the endpoints are directly parasite related.
Destruction of red blood cells (RBCs) is the end result of
malarial infection. None of the available in vitro assays uses
RBCs-related activity to determine endpoints. Furthermore,
the available in vitro assays do not test for drug selectivity
unless a separate assay on RBC toxicity is done. In this paper,
we report on a tetrazolium-based colorimetric selective assay
(MTT-based CSA) that uses indirect protection of RBCs
from parasite destruction as an endpoint for measuring the
eﬀect of drugs on parasites and also determines the possible
drug toxicity to the RBCs.
2.MaterialsandMethods
2.1. Drugs and Plant Extracts. Chloroquine diphosphate
(Sigma CQ) was obtained from SIGMA, St Louis, Mo, USA.
Also tested in comparison were formulated chloroquine2 Malaria Research and Treatment
(Troge Medical GmBH, Hamburg, Germany), formulated
chloroguanide (proguanil) (Zeneca Pharmaceuticals, UK),
formulated artesunate (Guilin Pharmaceutical Works, Chi-
na), and formulated oxytetracycline (Bimeda, Ireland) pur-
chased from a local pharmacy. Plant extracts GHX-26F and
GHX-6L are aqueous extracts from the fruits of Alchornea
cordifolia and the leaves of Ficus polita respectively. The
aqueous extracts were freeze-dried. Both plants are eﬀective
against human immunodeﬁciency virus in vitro [8]a n d
are suspected to have antiprotozoal activities. All drugs and
plant extracts were dissolved in culture medium and ﬁltered
through sterile 0.45µm ﬁlters.
2.2. Parasites. Strains 3D7 (chloroquine sensitive) and DD2
(chloroquine resistant) of P. falciparum were obtained from
Dr. Jorgehn Kurtzhals, Center for Medical Parasitology,
University of Copenhagan, Denmark.
2.3. Cell Cultures. P. falciparum infected and uninfected red
blood cells (RBCs) were cultured in RPMI 1640 (Gibco,
Parsley, UK) supplemented with 20mmol/mL L-glutamine
(Sigma-Aldrich Co. Ltd., UK), 20µg/mL gentamicin and
2.5µg/mL fungizone (Gibco, Parsley, UK), 10% albumax II
(GibcoBRL,GrandIsland,NY,USA),or10%normalhuman
AB serum (Sigma-Aldrich Co. Ltd., UK). The cultures were
ﬂushedwithagasmixtureconsistingof3%O2,6%CO 2,and
91% N2, sealed and incubated at 37◦C. For experiments in
96-wellmicrotitreplates,thecultureswereputinadesiccator
with a lit candle and nearly completely covered. As soon as
the candle went oﬀ, the desiccator was completely closed.
2.4. Determination of Optimum RBC Number and Incubation
Time. P. falciparum-strain-3D7-infected (1% parasitemia)
and uninfected cultures were incubated as described above
a n do b s e rv e dd a i l yf o rc o l o rd i ﬀerences between the two cul-
tures.Theparasite-infectedculturestartedbecomingvisually
pale from day 3. The diﬀerence in color between the infected
and uninfected cultures increased up to day 5. There was no
change in the observed paleness of the infected culture from
day5today6.Day5wasthereforeconsideredastheprobable
optimum incubation time for visually determined optimum
parasite-induced damage to RBCs. The number of RBCs in
culture that would give maximum diﬀerence between optical
densities (ODs) of uninfected and P. falciparum-infected
RBCs was then determined as follows. The numbers of
healthy RBCs in uninfected and parasite-infected stock cul-
tures were determined by the trypan blue exclusion method
andadjustedtobethesamepermilliliter.Twofoldserialdilu-
tions of stock cell cultures (uninfected or 5% infected) were
made and 100µL was put in wells of 96-well microtitre plates
that already contained 100µL of growth medium bringing
the total volume per well to 200µL. Each cell dilution was
put in six replicate wells. The cultures were incubated in a
desiccator as described above and after 5 days of incubation,
cell viability was determined by the MTT-based colorimetric
method as previously described [9]. Twenty microliters
(20µL) of MTT (7.5mg/mL) was added to each well and
the plates incubated at 37◦C for another 2h. One hundred
and ﬁfty microliters (150) µL of medium was then carefully
takenfromeachwellanddiscarded.Twohundredmicroliters
(200µL) of 10% Triton X-100 in acidiﬁed isopropanol was
added to each well in order to dissolve any formed formazan.
With the aid of a multichannel micropipettor, the contents
of each well were mixed several times, and the plates kept at
room temperature in the dark for 24h. The optical densities
of the wells were read by Emax Precision Microplate reader
(Molecular Devices Corporation, Menlo Park, Calif, USA) at
565nm and 690nm. Readings at 690nm were automatically
subtractedfromreadings at565nmby themicroplatereader.
The experiment was repeated once. The averages of all
readings were recorded for each dilution. A graph of cell
number versus diﬀerences in OD readings of uninfected and
infected wells was then plotted to determine the optimum
cell number that will give the highest OD reading diﬀerence
between uninfected and infected wells.
2.5. Determination of Optimum Parasitemia. Approximately,
23×106 cells per well were determined to give optimum dif-
ferenceinODreadingsbetweenuninfectedandP.falciparum
infected cells in the above experiment. Twenty-three million
(23 × 106) cells infected at various parasitemia ranging from
0% to 6% were put into wells of 96-well microtitre plates and
incubated at 37◦C for 5 days. Each parasitemia was tested
at 6 replicates. The cells were processed for MTT-based
colorimetric assay as described above. The average OD
readings at various levels of parasitemia were subtracted
from the average OD reading of control uninfected wells and
the values plotted against % parasitemia.
2.6. Tetrazolium-Based Colorimetric Selective Assay (MTT-
Based CSA). From the results of the foregoing experiments,
optimum time of incubation, optimum number of RBCs,
andoptimumparasitemiaweredeterminedtobe5days,23×
106 cells per well, and 3% parasitemia, respectively. The drug
inhibition experiments therefore utilized these three values
in the testing of chloroquine, chloroguanide (proguanil),
artesunate, oxytetracycline, and two plant extracts against P.
falciparum infection in RBC cultures. In the case of Sigma
CQ, 1.5% parasitemia was used. Drug or plant extract was
serially diluted, and a 100µL of each dilution was put into six
wells of 96-well microtitre plates. One hundred microliters
(100µL) of uninfected RBCs was added to three replicate
drug dilutions. One hundred microliters (100µL) of infected
RBCs was added to three other replicate drug dilutions.
Drug-medium controls in the top and bottom outer wells
were included in the experiments. The cultures were incu-
bated in a desiccator as described in the previous experi-
ments.TheMTT-basedcolorimetrictestwasthenperformed
onthecultures.ThepercentprotectionofRBCsfrommalaria
parasite destruction by diﬀerent drugs or plant extracts
concentrations were determined by the following formula:
Percent RBC Protection
=

1+
(ODT)Pf −(ODT)mock
(ODC)mock −(ODC)Pf

×100,
(1)
where (ODT)Pf is the average OD measured for a given
concentration of the test drug in P. falciparum-infectedMalaria Research and Treatment 3
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Figure 1: Eﬀects of number of red blood cells (a) and parasitemia (b) on P. falciparum cytopathicity, that is, optical density of mock-infected
RBCs minus optical density of parasite-infected RBCs [(ODC)mock −(ODC)infected]. Infection was done with strain 3D7.
RBCs; (ODT)mock is the average OD measured for a given
concentration of test drug in uninfected RBCs; (ODC)mock
is the average OD measured for the control untreated
uninfected RBCs; (ODC)Pf is the average OD measured
for the control untreated P. falciparum-infected RBCs.
The average percent RBC protection values for each three
replicates were plotted against the concentrations of drugs
and the concentrations needed to achieve 50% and 90%
RBC protection, that is, eﬀective concentrations (EC50 and
EC90) determined by regression analysis. The percent RBC
survival determined the extent of drug toxicity and was
calculated by the following formula:
Percent RBC Survival =
(ODT)mock −(ODT)cf
(ODC)mock −(ODC)cf
×100,
(2)
where (ODT)cf is the average OD measured for cell-free
treated wells; and (ODC)cf is the average OD measured for
cell-free untreated wells. These values were plotted against
the concentrations of the drugs and the concentrations
needed to reduce RBC survival by 50%, that is, 50%
cytotoxic concentrations (CC50) determined by regression
analysis. Anti-P. falciparum indices or selective indices (SI)
were then calculated as CC50/EC50.
2.7. Isotopic Microtest (IMT) Assay. The eﬀect of Sigma
CQ on P. falciparum strain DD2 was tested in the IMT
assay concurrently as in the MTT-based CSA. In the IMT
assay, the incubation was interrupted after 24 hours for the
additionof0.5µCiof 3H-hypoxanthine,andincubationcon-
tinued for additional 24 hours before measurement of 3H-
hypoxanthine uptake as published before [7]. The percent
inhibition was plotted against concentration of drug and the
EC50 and EC90 values determined by regression analysis.
3. Results
3.1. Optimum Incubation Time and Cell Number. By visual
examination, 5 days of incubation was found to give
maximum lysis in infected RBCs with very little cell death
in uninfected control cultures. Figure 1(a) shows the eﬀect
of number of RBCs on the diﬀerence in OD readings
between infected and uninfected RBCs. The cell number
that produced the highest diﬀerence in OD readings between
infected and uninfected RBCs was about 23 × 106 per well.
3.2. Optimum Parasitemia. Figure 1(b) shows the eﬀect of
parasitemia on the ability of RBCs to metabolize tetrazolium
to formazan. A parasitemia of 3% caused the optimum
damage to RBCs leading to high OD reading diﬀerence
between uninfected and infected RBCs of 0.92. The lowest
parasitemia at which enough damage to RBCs could be
detected was found to be 0.375% where the OD reading
diﬀerence between uninfected and infected RBCs was 0.2.
3.3.ComparativeActivitiesofDrugsandPlantExtractsagainst
DD2 and 3D7 Strains of P. falciparum. The antimalarial
activity of chloroquine diphosphate obtained from Sigma
was tested against strain DD2 in both the isotopic IMT and
the MTT-based CSA and the results are given in Figure 2
and Table 1. Sigma CQ was slightly more active in the IMT
than in the MTT-based CSA. The IMT unlike the MTT-
based CSA, does not include a toxicity test and is therefore
not applicable to the determination of selective index of a
drug. In the MTT-based CSA, formulated CQ (Figure 3(a)
and Table 1) like Sigma CQ had moderate activity against
this strain of P. falciparum. Proguanil (Figure 4(a)) and plant
extract GHX-26F (Figure 3(b) and Table 1) were minimally
eﬀective against DD2. Formulated artesunate (Figure 4(b))
and oxytetracycline (Figure 4(c)) were very eﬀective against
DD2. Formulated CQ and plant extract GHX-26F were
very eﬀective in the MTT-based CSA against chloroquine
sensitive 3D7 with SI (CC50/EC50)v a l u e so f>2,000 and
>69.4, respectively (Table 1). Figure 5 is from a separate
experiment done for pictures to be taken to demonstrate that
the eﬀects of drugs can be observed visually in the MTT-
based CSA. Clearly, formulated CQ and GHX-26F were very
eﬀectiveagainststrain3D7,whereasGHX-6Lhadnoactivity.4 Malaria Research and Treatment
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Figure 2: Anti-P. falciparum activity and toxicity of chloroquine (purchased from Sigma) tested in the IMT (a) and MTT-based CSA (b)
using parasite strain DD2.
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Figure 3: Anti-P. falciparum activity and toxicity of formulated chloroquine (a) and plant extract GHX-26F (b) tested in the MTT-based
CSA using parasite strains 3D7 and DD2.
4. Discussion
Determination of in vitro selectivity is crucial in identifying
new compounds with potentials as true antimalarial drugs.
There is no available in vitro antimalarial assay system that
determines drug selectivity. The term selectivity of action
in this paper refers to the extent to which the eﬀect of drug
is due to parasite events alone and not an indirect eﬀect
resulting from eﬀects on uninfected RBCs. This is very
important because a compound may destroy RBCs and
therefore prevent malaria parasite replication which will lead
to false-positive results. All available assays measure parasite-
related activity. Our MTT-based CSA measures RBC-related
activityofmetabolismoftetrazoliumintoformazan.Theend
result is a measure of the ability of a compound to indirectly
pr otectRBCsfr omP.falciparum-mediatedlysis.Theformula
for calculating the percent RBC protection is the same as
published for antihuman immunodeﬁciency drugs [9]. The
formula for calculating the percent RBC survival (toxicity)
has however been modiﬁed to account for plant extracts and
other drugs whose color may increase the background OD
reading. The maximum diﬀerence in OD values betweenMalaria Research and Treatment 5
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Figure4:Anti-P.falciparumactivityandtoxicityofformulatedproguanil(a),artesunate(b),andoxytetracycline(c)testedintheMTT-based
CSA using parasite strain DD2.
Table 1: Eﬀects of drugs and plant extracts against P. falciparum strains DD2 (A) and 3D7 (B) infection in RBCs.
Drug EC50 µg/mL EC90 µg/mL CC50 µg/mL SI (CC50/EC50)
(A)
Sigma CQa∗ 10.0 20.4 NA NA
Sigma CQb∗ 21.0 77.9 82.7 3.9
Formulated CQb 32.6 >50c >50c >1.5
GHX-6Lb >445c >445c >445c ND
GHX-26Fb 272.8 >340c >340c >1.2
(B)
Formulated CQb 0.025 0.05 >50c >2,000
GHX-6Lb >445c >445c >445c ND
GHX-26Fb 4.9 16.2 >340c >69.4
aTested by IMT, bTested by MTT-based CSA, ∗Parasitemia used was 1.5%. For the other tests, parasitemia used was 3.0%, cHighest concentration tested, SI:
selective index, NA: not applicable, ND: not determined.6 Malaria Research and Treatment
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Figure 5: Photographs of parasite strain 3D7-infected (bottom three replicates) and -uninfected (top three replicates) RBCs treated with
formulated chloroquine (a), plant extract GHX-6L (b), and plant extract GHX-26F (c) after the tetrazolium reaction. Concentrations are
given as µg/mL.
uninfected and infected RBCs may vary depending on the
source of RBCs used as a result of diﬀerences in certain
genetic factors involved in drug metabolism.
We used a speciﬁc number of RBCs instead of a speciﬁc
hematocrit because the formation of formazan is dependent
on healthy and metabolically active RBCs. Even though
approximately23×106 RBCs/wellwasdeterminedtogivethe
maximum diﬀerence between OD readings of mock-infected
andparasite-infectedRBCs,lowernumbersofRBCsthatgive
OD reading diﬀerence of at least 0.2 can be considered as
a minimum requirement (Figure 1(a)). A similar case can
be made for the parasitemia where reliable determinations
can be made using at least 0.375% parasitemia (Figure 1(b)).
Chloroquine diphosphate (SIGMA CQ) was tested in the
IMT and MTT-based CSA using 1.5% parasitemia similar to
other tests. For the other drugs, 3% parasitemia was used in
order to be able to clearly visualize the eﬀect of compounds
before and after the addition of tetrazolium without OD
reading by microplate reader. The choice of not changing
the medium during the 5 days of incubation was to allow
for the death of the parasites so that only the metabolic
activity of the RBCs would be determined by the MTT-based
assay.
As expected, chloroquine was not very eﬀective against
P. falciparum strain DD2 when tested in either the IMT or
MTT-based CSA. There was very little diﬀerence between
unformulated chloroquine bought from SIGMA and formu-
latedchloroquineboughtfromalocalpharmacyeventhough
the latter was tested at a higher parasitemia. Proguanil,
artesunate, and oxytetracycline were tested just to determine
their eﬀectiveness in inhibiting chloroquine-resistant DD2
induced RBC lysis. No attempt was made to ﬁnd EC50 con-
centrations of these dugs since only four concentrations of
each drug were tested. Proguanil needs to be activated to
a triazine derivative in vivo to have any signiﬁcant eﬀect
on P. falciparum infection [10]. The minimal activity of
proguanil observed against chloroquine resistant strain DD2
may be due to the little intrinsic activity of the drug. Arte-
sunate and oxytetracycline were very eﬀective against DD2
at concentrations with very little or no toxicity to RBCs.
Artesunate is a peroxide antimalarial drug which is activated
by haem and through a series of processes, it is suspectedMalaria Research and Treatment 7
to yield reactive species capable of alkylating key cellular
components and that cause parasite death [11, 12]. Oxyte-
tracycline inhibits protein synthesis and was expected to be
eﬀective against DD2 strain as conﬁrmed in our results.
The use of RBC-related activity to determine endpoint
drug eﬀect makes it inappropriate to compare our assay
with other available in vitro assays. Nevertheless, it would
suﬃce to say that our assay has the advantage of determining
the selectivity of drug action. We have used the MTT-based
CSA to show that one of two plants suspected to have
antiprotozoal activity, that is, Alchornea cordifolia, is indeed
very eﬀective against chloroquine-sensitive 3D7 with a high-
selective index. The development of an in vitro assay that
determines the selectivity of action would be even more
important for malarial parasite infection in RBCs from peo-
ple with glucose-6-phosphate dehydrogenase (G-6-PD) deﬁ-
ciency or those with congenital deﬁciency of nicotinamide
adenine dinucleotide (NADH) methemoglobin reductase in
whom antimalarial drug toxicity is of paramount concern.
One drawback that is common for all in vitro testing is that
the potential new drug may need liver enzyme metabolism
to the active form. An additional step of incubating the
compound with liver extract before testing will remedy
this drawback. Whereas existing in vitro antimalarial tests
may be faster and reliable for drugs with known toxicity
proﬁles, our MTT-based CSA stands out as providing results
on the selectivity of action of potential new antimalarial
drugs thereby allowing for early decision making for further
development. Finally, using the extent of RBCs destruction
to measure the endpoint gives us a much clearer assessment
of what is likely to occur in vivo.
5. Conclusions
A tetrazolium-based selective colorimetric assay was found
to be suitable in identifying potential new antimalarial
drugs. With the inclusion of toxicity studies in this assay,
antimalarial indices can be calculated to make sure that new
compounds are truly eﬀective against the parasite. The plant
extract Alchornea cordifolia was shown to be very eﬀective
against P. falciparum strain 3D7.
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